Cholera strain [CVD 103-HgR] vaccine is a Live Attenuated Vaccine owned by Emergent BioSolutions, and is involved in 7 clinical trials, of which 6 were completed, and 1 is ongoing.
PXVX-0200 elicits significantly higher serum vibriocidal antibodies against both inaba and ogawa strains of vibrio cholerae. It induces intestinal colonization and rapid immune responses. The vaccines candidate exhibit its therapeutic intervention by inducing antibodies against cholera infection.
The revenue for Cholera strain [CVD 103-HgR] vaccine is expected to reach a total of $475m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cholera strain [CVD 103-HgR] vaccine NPV Report.
Cholera strain [CVD 103-HgR] vaccine is currently owned by Emergent BioSolutions.
Cholera strain [CVD 103-HgR] vaccine Overview
Cholera vaccine (Vaxchora) is an active immunizing preparation. It is formulated as powder for suspension for oral route of administration. Vaxchora is indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.
PXVX-0200 (Vaxchora) vaccine is under development for the prevention of cholera. PXVX-0200 vaccine contains the CVD103-HgR strain. PXVX-0200 is developed by using adenoviral vaccine platform.
The vaccine candidate is also under development for the prevention of vibrio cholerae infections in pediatrics and adults.
Emergent BioSolutions Overview
Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$1,792.7 million for the fiscal year ended December 2021 (FY2021), an increase of 15.3% over FY2020. In FY2021, the company’s operating margin was 19.7%, compared to an operating margin of 27.9% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 19.6% in FY2020. The company reported revenues of US$240 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.
Quick View – Cholera strain [CVD 103-HgR] vaccine
|Highest Development Stage|